The use of AI in biotechnology is changing faster than the rules governing either technology
The convergence of AI and biotechnology blurs boundaries and challenges existing regulations designed to consider technologies separately.
Artificial intelligence (AI) is revolutionizing the field of biotechnology, advancing it at a pace that outstrips the regulatory frameworks in place. This rapid evolution poses significant challenges, particularly in the design and creation of novel viruses using AI. The development of AI-designed bacteriophages that selectively target and eliminate antibiotic-resistant strains of E. coli exemplifies the potential benefits of AI in biotechnology.
However, these advances also introduce new risks, as the same tools that can be harnessed for positive purposes may be exploited for harmful ends or produce unintended consequences that existing regulations cannot anticipate.
The convergence of AI and biotechnology, alongside other precision gene-editing technologies like CRISPR/Cas9 and synthetic biology, blurs the lines between computational design and biological systems. This convergence complicates regulatory approaches, which are often organized around specific technologies, organisms, or activities. The dual-use nature of these technologies—a quality that allows them to address problems while potentially creating new ones—adds another layer of complexity to the regulatory landscape.
The challenge for regulatory bodies is not merely how to ensure safety but how to foster beneficial research while anticipating and managing foreseeable risks. New Zealand is grappling with this issue, as evidenced by the stalled Gene Technology Bill aiming to replace outdated regulatory frameworks. The proposed system seeks a more flexible approach, exempting lower-risk gene-editing technologies while maintaining controls for activities posing higher risks.
Internationally, different approaches to biotechnology regulation offer insights into potential solutions. Australia's Gene Technology Act 2000 and the United States' Coordinated Framework for the Regulation of Biotechnology illustrate various strategies to balance innovation and risk. The EU, traditionally cautious, is adapting its rules to accommodate the rapid advancements in technologies like CRISPR, creating differentiated pathways for various levels of risk.
The key to effective biotechnology governance lies in developing adaptable regulatory frameworks that can distinguish between different levels of risk. This balance enables beneficial research to proceed without stifling innovation. The evolving nature of biotechnology demands regulatory systems capable of continuous adjustment to accommodate new technologies and their implications.
Thus, the goal is not to choose between innovation and regulation, but to create governance systems that remain flexible enough to navigate the complexities of this rapidly advancing field.
Written by urgent.news from The Conversation AU's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
